Hypomethylation-induced regulatory programs in T cells unveiled by transcriptomic analyses

Regulatory T cells (Tregs) are essential mediators of tolerance mitigating aberrant immune responses. While naturally occurring Treg (nTreg) development and function are directed by epigenetic events, induced Treg (iTreg) identity and mechanisms of action remain elusive. Mirroring the epigenetic circuits of nTregs, we and others have used hypomethylation agents (HAs) to ex vivo convert T cells into iTregs (HA-iTregs) and further showed that the suppressive properties of the HA-iTregs are predominantly confined in an emergent population, which de novo expresses the immunomodulatory molecule HLA-G, consequently providing a surface marker for isolation of the suppressive HA-iTreg compartment (G+ cells). We isolated the HA-induced G+ cells and their G− counterparts and employed high-throughput RNA-sequencing (RNA-seq) analyses to uncover the G+-specific transcriptomic changes guiding T cells toward a regulatory trajectory upon their exposure to HA. We found a distinct transcriptional upregulation of G+ cells accompanied by enrichment of immune-response–related pathways. Although single-cell RNA-seq profiling revealed regulatory G+ cells to have molecular features akin to nTregs, when assessed in conjunction with the comparative transcriptomic analysis and profiling of secreted cytokines against the non-suppressive G− cells, FOXP3 and other T-helper signatures appear to play a minor role in their suppressive phenotype. We found an ectopic expression of IDO-1 and CCL17/22 in G+ cells, denoting that in vitro exposure of T cells to HA may well unlock myeloid suppressor genes. This report provides transcriptional data shaping the molecular identity of a highly purified and potent HA-iTreg population and hints toward ectopic myeloid-specific molecular mechanisms mediating HA-iTreg function.

[1]  G. Karavalakis,et al.  Study protocol: Phase I/II trial of induced HLA-G+ regulatory T cells in patients undergoing allogeneic hematopoietic cell transplantation from an HLA-matched sibling donor , 2023, Frontiers in Medicine.

[2]  A. Pradier,et al.  Analysis of T cell Repertoire and Transcriptome Identifies Mechanisms of Regulatory T cell (Treg) Suppression of GvHD. , 2022, Blood.

[3]  Mark M. Davis,et al.  Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients , 2021, Science Translational Medicine.

[4]  M. Roncarolo,et al.  Pre-clinical development and molecular characterization of an engineered type 1 regulatory T-cell product suitable for immunotherapy. , 2021, Cytotherapy.

[5]  M. Kobor,et al.  Optimized CRISPR-mediated gene knockin reveals FOXP3-independent maintenance of human Treg identity. , 2021, Cell reports.

[6]  Andrew J. Pollard,et al.  RNA2HLA: HLA-based quality control of RNA-seq datasets , 2021, Briefings Bioinform..

[7]  Y. Okada,et al.  Regulatory T Cell-Specific Epigenomic Region Variants Are a Key Determinant of Susceptibility to Common Autoimmune Diseases. , 2020, Immunity.

[8]  A. Thomson,et al.  In situ recruitment of regulatory T cells promotes donor-specific tolerance in vascularized composite allotransplantation , 2020, Science Advances.

[9]  J. Bluestone,et al.  Treg cell-based therapies: challenges and perspectives , 2019, Nature Reviews Immunology.

[10]  D. Miklos,et al.  Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients. , 2019, JCI insight.

[11]  I. Pe’er,et al.  arcasHLA: high-resolution HLA typing from RNAseq , 2018, bioRxiv.

[12]  A. Sgourou,et al.  Simple in vitro generation of human leukocyte antigen-G-expressing T-regulatory cells through pharmacological hypomethylation for adoptive cellular immunotherapy against graft-versus-host disease. , 2017, Cytotherapy.

[13]  Lirong Pei,et al.  Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers , 2017, Cancer Immunology Research.

[14]  M. Obach,et al.  CCL22 Prevents Rejection of Mouse Islet Allografts and Induces Donor-Specific Tolerance , 2015, Cell transplantation.

[15]  H. Wiendl,et al.  Human CD4+HLA‐G+ regulatory T cells are potent suppressors of graft‐versus‐host disease in vivo , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  P. Oefner,et al.  CLL-cells induce IDOhi CD14+HLA-DRlo myeloid-derived suppressor cells that inhibit T-cell responses and promote TRegs. , 2014, Blood.

[17]  Y. Hildebrandt,et al.  5-Azacytidine Promotes an Inhibitory T-Cell Phenotype and Impairs Immune Mediated Antileukemic Activity , 2014, Mediators of inflammation.

[18]  J. Castle,et al.  HLA typing from RNA-Seq sequence reads , 2012, Genome Medicine.

[19]  K. Nakai,et al.  T cell receptor stimulation-induced epigenetic changes and Foxp3 expression are independent and complementary events required for Treg cell development. , 2012, Immunity.

[20]  H. Papadaki,et al.  Identification of a novel HLA-G+ regulatory population in blood: expansion after allogeneic transplantation and de novo HLA-G expression at graft-versus-host disease sites , 2012, Haematologica.

[21]  M. Levings,et al.  Prevention of murine autoimmune diabetes by CCL22-mediated Treg recruitment to the pancreatic islets. , 2011, The Journal of clinical investigation.

[22]  J. Fechner,et al.  An Interaction between Kynurenine and the Aryl Hydrocarbon Receptor Can Generate Regulatory T Cells , 2010, The Journal of Immunology.

[23]  W. Shannon,et al.  In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. , 2010, Blood.

[24]  D. Munn,et al.  Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality. , 2009, Blood.

[25]  J. Blay,et al.  Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. , 2009, Cancer research.

[26]  N. Rouas-Freiss,et al.  Beyond the increasing complexity of the immunomodulatory HLA-G molecule. , 2008, Blood.

[27]  H. Wiendl,et al.  HLA-G expression defines a novel regulatory T-cell subset present in human peripheral blood and sites of inflammation. , 2007, Blood.

[28]  T. Glant,et al.  Inhibition of indoleamine 2,3-dioxygenase-mediated tryptophan catabolism accelerates collagen-induced arthritis in mice , 2007, Arthritis research & therapy.

[29]  D. Munn,et al.  Indoleamine 2,3-dioxygenase and tumor-induced tolerance. , 2007, The Journal of clinical investigation.

[30]  A. Boasso,et al.  Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells. , 2005, Blood.

[31]  G. Prendergast,et al.  Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy , 2005, Nature Medicine.

[32]  C. Fathman,et al.  CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation , 2003, Nature Medicine.

[33]  F. Romerio,et al.  Human primary CD4 + T cells activated in the presence of IFN-alpha 2b express functional indoleamine 2,3-dioxygenase. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[34]  D. Munn,et al.  Prevention of allogeneic fetal rejection by tryptophan catabolism. , 1998, Science.

[35]  Michael S. Krzemnicki,et al.  Challenges and perspectives , 2009 .